Navamedic: Q1 2006 presentation at Felix 3 May at 08:00
Navamedic ASA invites to a presentation of the company’s Q1 2006 results on 3 May 2006. The presentation will take place at Felix Conference Centre at Aker Brygge, Bryggetorget 3, 0114 Oslo, and will start at 08:00 a.m. Participants are requested to register at firstname.lastname@example.org or by calling +47 67 11 25 40.
(Lysaker, Norway, 28 April, 2006) The company’s financial calendar for 2006 runs as follows:
3 May 2006: Q1 2006 results, presentation at Felix Conference Center
23 August 2006: Q2 2006 results, presentation at Felix Conference Center
25 October 2006: Q3 2006 results, presentation at Felix Conference Center
13 February 2007: Q4 2006 results, presentation at Felix Conference Center
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world’s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company’s products will be sold through a network of sales, marketing and distribution partners. Navamedic’s product Glucomed® has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.
- Contact Information
- Jon W. Ringvold
- Navamedic ASA
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.